Format

Send to

Choose Destination
Surg Oncol. 2017 Dec;26(4):333-337. doi: 10.1016/j.suronc.2017.07.002. Epub 2017 Jul 13.

Beta-elemene treatment is associated with improved outcomes of patients with esophageal squamous cell carcinoma.

Author information

1
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, People's Republic of China.
2
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, People's Republic of China. Electronic address: qinyanru2017@163.com.

Abstract

PURPOSE:

To investigate the therapeutic effects of concurrent preoperative β-elemene treatment in patients with esophageal squamous cell carcinoma who received concurrent chemoradiotherpay followed by surgery.

METHOD:

The clinicopathological parameters and outcomes of 102 patients with esophageal squamous cell carcinoma were studied and compared between patients treated with and without β-elemene.

RESULTS:

β-elemene treatment could prolong the overall survival and progression-free survival. The 3-year overall survival rate was also increased by β-elemene treatment. β-elemene treatment was an independent prognostic factor for both overall survival and progression-free survival. Occurrence of toxicities associated with chemoradiotherapy was decreased by β-elemene treatment.

CONCLUSIONS:

Findings in this study suggested that β-elemene treatment provided survival benefits and reduced chemoradiotherapy-associated toxicities in patients with esophageal squamous cell carcinoma.

KEYWORDS:

Esophageal squamous cell carcinoma; Overall survival; Prognosis; Progression-free survival; β-Elemene

PMID:
29113648
DOI:
10.1016/j.suronc.2017.07.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center